ATE533474T1 - Durch nassgranulation hergestellte stabile und fertig gelöste zusammensetzungen aus candesartan- cilexetil - Google Patents

Durch nassgranulation hergestellte stabile und fertig gelöste zusammensetzungen aus candesartan- cilexetil

Info

Publication number
ATE533474T1
ATE533474T1 AT08016396T AT08016396T ATE533474T1 AT E533474 T1 ATE533474 T1 AT E533474T1 AT 08016396 T AT08016396 T AT 08016396T AT 08016396 T AT08016396 T AT 08016396T AT E533474 T1 ATE533474 T1 AT E533474T1
Authority
AT
Austria
Prior art keywords
compositions
cilexetil
candesartan
finished
stable
Prior art date
Application number
AT08016396T
Other languages
English (en)
Inventor
Frank Gindullis
Sergio Simoes
Da Silva Alberto Gabriel Leitaeo
Original Assignee
Helm Ag
Bluepharma Ind Farmaceutica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helm Ag, Bluepharma Ind Farmaceutica S A filed Critical Helm Ag
Application granted granted Critical
Publication of ATE533474T1 publication Critical patent/ATE533474T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT08016396T 2008-09-17 2008-09-17 Durch nassgranulation hergestellte stabile und fertig gelöste zusammensetzungen aus candesartan- cilexetil ATE533474T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08016396A EP2165702B1 (de) 2008-09-17 2008-09-17 Durch Nassgranulation hergestellte stabile und fertig gelöste Zusammensetzungen aus Candesartan-Cilexetil

Publications (1)

Publication Number Publication Date
ATE533474T1 true ATE533474T1 (de) 2011-12-15

Family

ID=40291309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08016396T ATE533474T1 (de) 2008-09-17 2008-09-17 Durch nassgranulation hergestellte stabile und fertig gelöste zusammensetzungen aus candesartan- cilexetil

Country Status (8)

Country Link
EP (1) EP2165702B1 (de)
AT (1) ATE533474T1 (de)
DK (1) DK2165702T3 (de)
ES (1) ES2377552T3 (de)
HR (1) HRP20120134T1 (de)
PL (1) PL2165702T3 (de)
PT (1) PT2165702E (de)
SI (1) SI2165702T1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5917844B2 (ja) * 2011-06-24 2016-05-18 日本ケミファ株式会社 カンデサルタンシレキセチル製剤
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
WO2014119667A1 (ja) * 2013-01-30 2014-08-07 沢井製薬株式会社 カンデサルタンシレキセチル含有医薬組成物
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3219309A1 (de) * 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Pharmazeutische zusammensetzung mit fixdosierungskombination von amlodipin, candesartan cilexetil und hydrochlorothiazid zur behandlung von bluthochdruck
JP2018141011A (ja) * 2018-05-24 2018-09-13 日本ケミファ株式会社 カンデサルタン シレキセチル製剤
KR102730602B1 (ko) * 2021-06-24 2024-11-18 주식회사 종근당 칸데사르탄, 암로디핀 및 아토르바스타틴을 포함하는 약제학적 복합제제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146683B1 (de) 1981-07-31 1987-11-19 Siemens Aktiengesellschaft Wechselrichter
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (de) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
TWI239247B (en) 2001-06-14 2005-09-11 Otsuka Pharma Co Ltd Pharmaceutical composition
PE20030324A1 (es) 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
EP1592406A2 (de) 2003-02-13 2005-11-09 Phares Pharmaceutical Research N.V. Lipophile zusammensetzungen
WO2005079751A2 (en) * 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
EP1835890A2 (de) 2005-01-06 2007-09-26 Elan Pharma International Limited Candesartan-nanopartikelformulierungen
WO2006079496A1 (en) 2005-01-26 2006-08-03 Lek Pharmaceuticals D.D. New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
KR20080042039A (ko) 2005-04-18 2008-05-14 루비콘 리서치 피브이티. 엘티디. 생물학적으로 강화된 조성물
JP2008540644A (ja) 2005-07-15 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド 新規粒質化方法及びそれから生成される粒質物
EP1973531A2 (de) 2006-01-02 2008-10-01 Rubicon Research Private Limited Pharmazeutische zusammensetzungen
EP2099431B1 (de) * 2006-11-28 2013-06-05 Laboratorios Liconsa, S.A. Stabilisierte feste pharmazeutische zusammensetzung von candesartan cilexetil
EP1961412A1 (de) * 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Selbstmikroemulgierende Arzneimittelabgabesysteme
EP1952806A1 (de) 2007-02-01 2008-08-06 Helm AG Herstellungsverfahren für Candesartan-Adsorbate
ATE479427T1 (de) * 2007-03-08 2010-09-15 Teva Pharma Pharmazeutische zusammensetzung mit candesartan- cilexetil
EP1997479A1 (de) 2007-05-31 2008-12-03 Helm AG Stabilisierte amorphe Candesartancilexetil-haltige Zubereitungen zur oralen Anwendung

Also Published As

Publication number Publication date
PL2165702T3 (pl) 2012-04-30
HRP20120134T1 (hr) 2012-03-31
PT2165702E (pt) 2012-02-07
SI2165702T1 (sl) 2012-05-31
EP2165702A1 (de) 2010-03-24
ES2377552T3 (es) 2012-03-28
EP2165702B1 (de) 2011-11-16
DK2165702T3 (da) 2012-03-05

Similar Documents

Publication Publication Date Title
ATE533474T1 (de) Durch nassgranulation hergestellte stabile und fertig gelöste zusammensetzungen aus candesartan- cilexetil
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
NO20090029L (no) Pyrrolopyrimidiner for farmasoytiske formuleringer
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
WO2009089011A8 (en) Resveratrol formulations
EA201190020A1 (ru) Производные изоиндола в качестве ингибиторов васе и их применение
TW200700012A (en) Oil and fat composition
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
EA201791321A1 (ru) Составы ингибитора lfa-1
ATE513820T1 (de) Neue benzamidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
CR20110209A (es) Composición farmacéutica sólida
WO2008074803A8 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
WO2010056527A3 (en) B-biphenyl sulfonamide compounds as ion channel modulators
ATE455111T1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors